loading...| Preferred Name | Cabozantinib | |
| Synonyms |
|
|
| Definitions |
An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C52200 |
|
| CAS_Registry |
849217-68-1 |
|
| Chemical_Formula |
C28H24FN3O5 |
|
| code |
C52200 |
|
| Contributing_Source |
CTRP FDA PCDC |
|
| definition |
An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression. |
|
| Display_Name |
Cabozantinib |
|
| FDA_UNII_Code |
1C39JW444G |
|
| Has_Salt_Form | ||
| Has_Target |
http://purl.obolibrary.org/obo/NCIT_C26203 http://purl.obolibrary.org/obo/NCIT_C17475 http://purl.obolibrary.org/obo/NCIT_C18539 http://purl.obolibrary.org/obo/NCIT_C18488 http://purl.obolibrary.org/obo/NCIT_C17328 http://purl.obolibrary.org/obo/NCIT_C26202 http://purl.obolibrary.org/obo/NCIT_C18186 http://purl.obolibrary.org/obo/NCIT_C17975 |
|
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C179531 http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C179478 |
|
| Is_Value_For_GDC_Property | ||
| label |
Cabozantinib |
|
| Legacy Concept Name |
XL184 |
|
| Maps_To |
Cabozantinib |
|
| Preferred_Name |
Cabozantinib |
|
| prefixIRI |
NCIT:C52200 |
|
| prefLabel |
Cabozantinib |
|
| Semantic_Type |
Pharmacologic Substance |
|
| UMLS_CUI |
C3181682 |
|
| subClassOf |
http://purl.obolibrary.org/obo/NCIT_C93259 |